The Ledger

TECH

Bio-Techne CorpHealth Careinsider_universe

Last close $71.01Jun 28, 2026

Day +0.01%

Currently held

Agent 8 — Dip Buyer (Peer-Aware)long
16 sh @ $49.52 · stop $44.13
+$342.29 unrealized
Agent 6 — Options Momentumlong
1 contracts · CALL $59 exp Jul 23, 2026 · entry $3.30
+$642.95 unrealized

Everything we've seen

·Jun 29, 3:32 PMstreamnews
1 Momentum Stock with Impressive Fundamentals and 2 We Find Risky
The stocks featured in this article are seeing some big returns. Over the past month, they’ve outpaced the market due to some combination of positive news, upbeat results, or supportive macro developments. As such, investors are taking notice and bidding up shares.
·Jun 29, 3:32 PMstreamnews
Citigroup Downgrades Bio-Techne to Neutral, Raises Price Target to $73
Citigroup analyst Patrick Donnelly downgrades Bio-Techne (NASDAQ:TECH) from Buy to Neutral and raises the price target from $70 to $73.
·Jun 29, 3:17 PMstreamnews
1 Momentum Stock with Impressive Fundamentals and 2 We Find Risky
The stocks featured in this article are seeing some big returns. Over the past month, they’ve outpaced the market due to some combination of positive news, upbeat results, or supportive macro developments. As such, investors are taking notice and bidding up shares.
·Jun 29, 3:17 PMstreamnews
Citigroup Downgrades Bio-Techne to Neutral, Raises Price Target to $73
Citigroup analyst Patrick Donnelly downgrades Bio-Techne (NASDAQ:TECH) from Buy to Neutral and raises the price target from $70 to $73.
·Jun 29, 3:03 PMstreamnews
1 Momentum Stock with Impressive Fundamentals and 2 We Find Risky
The stocks featured in this article are seeing some big returns. Over the past month, they’ve outpaced the market due to some combination of positive news, upbeat results, or supportive macro developments. As such, investors are taking notice and bidding up shares.
·Jun 29, 3:03 PMstreamnews
Citigroup Downgrades Bio-Techne to Neutral, Raises Price Target to $73
Citigroup analyst Patrick Donnelly downgrades Bio-Techne (NASDAQ:TECH) from Buy to Neutral and raises the price target from $70 to $73.
·Jun 29, 2:47 PMstreamnews
1 Momentum Stock with Impressive Fundamentals and 2 We Find Risky
The stocks featured in this article are seeing some big returns. Over the past month, they’ve outpaced the market due to some combination of positive news, upbeat results, or supportive macro developments. As such, investors are taking notice and bidding up shares.
·Jun 29, 2:32 PMstreamnews
1 Momentum Stock with Impressive Fundamentals and 2 We Find Risky
The stocks featured in this article are seeing some big returns. Over the past month, they’ve outpaced the market due to some combination of positive news, upbeat results, or supportive macro developments. As such, investors are taking notice and bidding up shares.
·Jun 29, 1:47 PMstreamnews
Which S&P500 stocks have an unusual volume on Monday?
Curious about which S&P500 stocks are generating unusual volume on Monday? Find out below.
❖Jun 29, 1:05 PMnewsvia finnhub
Which S&P500 stocks have an unusual volume on Monday?
Curious about which S&P500 stocks are generating unusual volume on Monday? Find out below.
·Jun 29, 12:33 PMstreamnews
Citigroup Downgrades Bio-Techne to Neutral, Raises Price Target to $73
Citigroup analyst Patrick Donnelly downgrades Bio-Techne (NASDAQ:TECH) from Buy to Neutral and raises the price target from $70 to $73.
·Jun 29, 6:18 AMstreamnews
1 Momentum Stock with Impressive Fundamentals and 2 We Find Risky
The stocks featured in this article are seeing some big returns. Over the past month, they’ve outpaced the market due to some combination of positive news, upbeat results, or supportive macro developments. As such, investors are taking notice and bidding up shares.
❖Jun 29, 5:09 AMnewsvia finnhub
Citigroup Downgrades Bio-Techne to Neutral, Raises Price Target to $73
Citigroup analyst Patrick Donnelly downgrades Bio-Techne (NASDAQ:TECH) from Buy to Neutral and raises the price target from $70 to $73.
❖Jun 29, 4:25 AMnewsvia finnhub
1 Momentum Stock with Impressive Fundamentals and 2 We Find Risky
The stocks featured in this article are seeing some big returns. Over the past month, they’ve outpaced the market due to some combination of positive news, upbeat results, or supportive macro developments. As such, investors are taking notice and bidding up shares.
❖Jun 26, 1:28 PMnewsvia finnhub
The $11 Billion Reason TECH Stock Is Up Today
Bio-Techne stock rallies as Merck announces an agreement to acquire it for $73 per share. But is there any further upside left in TECH shares?
❖Jun 26, 10:13 AMnewsvia finnhub
Merck KGaA to acquire Bio-Techne in $11.3 billion deal
The deal, Merck's largest since its Sigma-Aldrich buyout, expands its presence in proteins, spatial biology, and cell and gene therapy
❖Jun 26, 9:22 AMnewsvia finnhub
Company News for Jun 26, 2026
Companies in The News Are: BB, MKC, META, TECH, MKKGY
❖Jun 26, 8:07 AMnewsvia finnhub
Bio-Techne (TECH) Agrees To $11.5 Billion Merck KGaA Buyout
Merck KGaA has agreed to acquire Bio-Techne (NasdaqGS:TECH) for $11.5b in an all cash deal. Bio-Techne's board has unanimously approved the transaction, which is now subject to regulatory review. The companies highlight expected synergies and accretion to Merck KGaA’s earnings following completion. For investors tracking Bio-Techne, the agreed $11.5b acquisition by Merck KGaA lands after a sharp move in the stock, with NasdaqGS:TECH up 22% over the past week and 47% over the past month. The...
❖Jun 26, 7:23 AMnewsvia finnhub
Stephens & Co. Downgrades Bio-Techne to Equal-Weight, Raises Price Target to $73
Stephens & Co. analyst Steven Etoch downgrades Bio-Techne (NASDAQ:TECH) from Overweight to Equal-Weight and raises the price target from $68 to $73.
❖Jun 26, 6:49 AMnewsvia finnhub
William Blair Downgrades Bio-Techne to Market Perform
William Blair analyst Matt Larew downgrades Bio-Techne (NASDAQ:TECH) from Outperform to Market Perform.
❖Jun 26, 5:03 AMnewsvia finnhub
Bio-Techne Corporation (TECH) Merck KGaA - M&A Call - Slideshow
2026-06-26. The following slide deck was published by Bio-Techne Corporation in conjunction with this event.
❖Jun 26, 5:02 AMnewsvia finnhub
Bio-Techne Corporation (TECH) M&A Call Transcript
Bio-Techne Corporation (TECH) M&A Call June 25, 2026 8:00 AM EDTCompany ParticipantsFlorian Schraeder - Head of Investor RelationsKai Beckmann - CEO...
❖Jun 26, 3:18 AMnewsvia finnhub
Baird Maintains Neutral on Bio-Techne, Raises Price Target to $73
Baird analyst Catherine Schulte maintains Bio-Techne (NASDAQ:TECH) with a Neutral and raises the price target from $49 to $73.
❖Jun 26, 2:12 AMnewsvia finnhub
Bio-Techne To Pay Termination Fee Of $230.5M To Merck KGaA In Event That Deal Isn't Consummated; Merck KGaA To Pay Fee Of $576.1M If Deal Terminated
Termination Fees The Company will be required to pay to Parent a termination fee equal to $230,455,000 (the "Company Termination Fee"): · If (A) the Merger Agreement is validly terminated (i) by either Parent
❖Jun 26, 12:01 AMnewsvia finnhub
Germany’s Merck Pumps Up Life Sciences Biz with $11.3B Bio-Techne Deal
Merck KGaA's agreement to buy Bio-Techne for $11.3 billion strengthens its hold in life sciences, especially drug discovery and gene therapy.
❖Jun 25, 11:18 PMnewsvia finnhub
Bio-Techne (TECH) Soars 20% on Merck $11.3B Merger
Bio-Techne Corp. (NASDAQ:TECH) is one of the 9 Stocks Winning by Double Digits. Bio-Techne rallied for a third straight day on Thursday, surging 20.08 percent to close at $70.70 apiece, as investors gobbled up shares following news that it is merging with pharmaceutical giant Merck for $11.3 billion. In a statement, Bio-Techne Corp. (NASDAQ:TECH) said […]
▣Jun 25, 8:00 PMjournalmanual
Agent 8 — Dip Buyer (Peer-Aware) closed long 15 @ $70.22 (+$310.48)
Staged exit (1/2.0): close $70.70 ≥ target $62.47. Selling 15/31 sh, trailing remainder.
❖Jun 25, 6:45 PMnewsvia finnhub
Merck KGaA: Bio-Techne Acquisition Improves Quality, But The Stock Seems Fully Valued (Downgrade)
Merck KGaA (MKGAF) Q1 beat and Bio-Techne deal drive upside, but valuation looks full. Read here for a detailed investment analysis.
❖Jun 25, 5:43 PMnewsvia finnhub
Stock Market Today, June 25: Bio-Techne Surges After Merck KGaA Announces $73-Per-Share Cash Acquisition Offer
On June 25, 2026, investors tracked deal progress as Bio-Techne shares responded to the proposed buyout terms.
❖Jun 25, 3:48 PMnewsvia finnhub
Sector Update: Healthcare Stocks Gain Late Afternoon
Healthcare stocks rose late Thursday afternoon with the NYSE Healthcare Index gaining 1.7% and the S
❖Jun 25, 3:12 PMnewsvia finnhub
Bio-Techne Is a Top S&P 500 Stock. Germany’s Merck Is Paying a 24% Premium for the Company.
Shares of Bio-Techne surged Thursday after Germany’s Merck KGaA announced it agreed to purchase the company for $11.3 billion. Bio-Techne stock jumped 20% to $70.55 on Thursday, placing it near the top of the for the trading session and set to log its best daily percentage gain since May 1, 2003, according to Dow Jones Market Data. Merck KGaA plans to acquire Bio-Techne for $73 a share, according to the media release, representing a 24% premium based on the stock’s closing price from Wednesday.
❖Jun 25, 3:05 PMnewsvia finnhub
Top S&P500 movers in Thursday's session
Stay updated with the movement of S&P500 stocks in today's session. Discover which S&P500 stocks are making waves on Thursday.
❖Jun 25, 2:05 PMnewsvia finnhub
These S&P500 stocks are the most active in today's session
Explore the S&P500 index on Thursday and find out which stocks are the most active in today's session. Stay updated with the stocks that are capturing market interest and driving market movements.
!Jun 25, 1:35 PMsignal
Agent 6 — Options Momentum — insufficient_capital
❖Jun 25, 1:33 PMnewsvia finnhub
Update: US Equity Indexes Mixed as Tech Bulls Whistle Past Micron's Blockbuster Results, Inflation Surges to Three-Year High
(Updates with index/price moves, macroeconomic data, and company/political news from the first parag
❖Jun 25, 1:05 PMnewsvia finnhub
These S&P500 stocks have an unusual volume in today's session
Let's take a closer look at the S&P500 stocks with an unusual volume in today's session on Thursday. Stay informed about the market activity below.
❖Jun 25, 12:35 PMnewsvia finnhub
Explore the top gainers and losers within the S&P500 index in today's session.
Get insights into the S&P500 index performance on Thursday. Explore the top gainers and losers within the S&P500 index in today's session.
❖Jun 25, 11:40 AMnewsvia finnhub
Top Midday Stories: Micron Shares Soar After Estimate-Topping Earnings Results; Bio-Techne to be Acquired by Merck for $11.3 Billion
The Dow Jones Industrial Average and S&P 500 were up in late-morning trading Thursday, while the Nas
❖Jun 25, 10:35 AMnewsvia finnhub
Which S&P500 stocks are gapping on Thursday?
Looking for the S&P500 stocks that are experiencing notable gaps on Thursday? Find out which stocks are gapping up and gapping down in the S&P500 index during today's session.
❖Jun 25, 10:30 AMnewsvia finnhub
These stocks are gapping in today's session
The session on Thursday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session.
❖Jun 25, 10:30 AMnewsvia finnhub
Bio-Techne Is Today’s Top S&P 500 Stock. Germany’s Merck Is Paying a 24% Premium for the Company.
Shares of Bio-Techne surged Thursday after Germany’s Merck KGaA announced it agreed to purchase the company for $11.3 billion. Bio-Techne stock jumped 19% to $70.25 on Thursday, leading the for the trading session and set to log its best daily percentage gain since May 1, 2003, according to Dow Jones Market Data. Merck KGaA plans to acquire Bio-Techne for $73 a share, according to the media release, representing a 24% premium based on the stock’s closing price from Wednesday.
❖Jun 25, 10:22 AMnewsvia finnhub
Merck KGaA to buy Bio-Techne for $11.3bn in life science footprint expansion
The deal is Merck’s largest since 2015, when it spent $17bn on acquiring Sigma-Aldrich, also a life sciences specialist.
❖Jun 25, 10:14 AMnewsvia finnhub
Micron Rallies 15%, Apple Sinks 6% On Memory Costs: Stock Market Today
Micron's blowout earnings powered memory and chip stocks higher, but the broad stock market rally stalled by midday as S&P 500 slipped.
❖Jun 25, 9:48 AMnewsvia finnhub
Germany's Merck KGaA Swoops In With $11.3 Billion Medtech Buyout
Germany's Merck KGaA pledged Thursday to buy Bio-Techne for $11.3 billion. The deal expands its portfolio of life sciences tools.
❖Jun 25, 9:11 AMnewsvia finnhub
Micron Rallies 15%, Apple Sinks 6% On Memory Costs: Stock Market Today
Micron's blowout earnings powered memory and chip stocks higher, but the broad rally stalled by midday as the S&P 500 slipped.
❖Jun 25, 9:07 AMnewsvia finnhub
Bio-Techne to Be Acquired by Germany's Merck in $11.3 Billion Deal
Bio-Techne (TECH) said Thursday it has agreed to be acquired by Merck KGaA in an all-cash deal with
❖Jun 25, 9:05 AMnewsvia finnhub
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Atlantic International (NASDAQ:ATLN) shares increased by 41.0% to $1.1 during Thursday's regular session. The company's market cap stands at $59.4 million. As per the press release, Q1 earnings came out
❖Jun 25, 8:35 AMnewsvia finnhub
Stocks making the biggest moves midday: BlackBerry, Kymera Therapeutics, Apple, Wendy's & more
These are the stocks posting the largest moves midday.
❖Jun 25, 8:35 AMnewsvia finnhub
Stay updated with the S&P500 stocks that are on the move in today's pre-market session.
As the US market prepares to open on Thursday, let's get an early glimpse into the pre-market session and identify the S&P500 stocks leading the pack in terms of gains and losses.
❖Jun 25, 8:31 AMnewsvia finnhub
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Thursday as Investors Embrace AI Growth Themes, Reduced Middle East Risks
The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.7%, and the actively tra
❖Jun 25, 8:30 AMnewsvia finnhub
Which stocks are moving before the opening bell on Thursday?
The US market session of Thursday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today.
❖Jun 25, 7:43 AMnewsvia finnhub
Stocks Rise Pre-Bell as Traders Assess Micron Results, Await Key Inflation Data
US equity markets were pointing higher before the opening bell Thursday as traders parse Micron Tech
❖Jun 25, 7:18 AMnewsvia finnhub
Germany’s Merck Is Buying Bio-Techne for $11.3 Billion
Shares of Bio-Techne surged before the opening bell on Thursday after Germany’s Merck KGaA announced it has agreed to purchase the company for $11.3 billion. Bio-Techne stock jumped 21% to $70.95 in premarket trading on Thursday. Merck KGaA plans to acquire Bio-Techne for $73 a share, according to the media release, representing a 24% premium based on the stock’s closing price from Wednesday.
❖Jun 25, 6:57 AMnewsvia finnhub
Germany’s Merck to Acquire Bio-Techne in $11.3 Billion Deal
Germany’s Merck KGaA has announced a major acquisition agreement to buy U. S.
❖Jun 25, 6:10 AMnewsvia finnhub
Merck KGaA, Darmstadt, Germany, Agrees to Acquire Bio-Techne, Strengthening Leadership Position in Fast-Growing Life Sciences Markets
Merck KGaA, Darmstadt, Germany, a leading science and technology company, and Bio-Techne Corporation (NASDAQ: TECH), a Minneapolis-based global provider of life science tools, analytical technologies, and consumables, today entered into a definitive agreement pursuant to which Merck KGaA, Darmstadt, Germany, will, subject to customary closing conditions, acquire Bio-Techne for US$73 per share in cash, representing a total enterprise value of approximately US$11.3 billion (EUR 9.9 billion), a 36%
❖Jun 25, 5:55 AMnewsvia finnhub
Acuity Posts Strong Q3 Results, Joins BlackBerry, MillerKnoll, Qualcomm And Other Big Stocks Moving Higher On Thursday
Dow Jones index gained 200 points; Acuity Inc (NYSE: AYI) reported better-than-expected financial results, shares rose 17.1%; other big stocks also gained.
❖Jun 25, 5:34 AMnewsvia finnhub
Merck Germany Lands Bio-Techne In $11.3 Billion Cash Deal
Merck KGaA is acquiring Bio-Techne in an $11.3B all-cash deal to expand its life science, diagnostics, and bioprocessing footprint.
❖Jun 25, 4:05 AMnewsvia finnhub
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Adicet Bio (NASDAQ:ACET) stock moved upwards by 22.9% to $10.14 during Thursday's pre-market session. The market value of their outstanding shares is at $77.1 million. Bio-Techne (NASDAQ:TECH) stock moved
❖Jun 25, 3:38 AMnewsvia finnhub
Stocks making the biggest moves premarket: Micron, Qualcomm, IBM, Wendy's & more
These are the stocks posting the largest moves in the premarket.
❖Jun 25, 2:21 AMnewsvia finnhub
CORRECTION: Germany's Merck KGaA To Acquire Bio-Techne At $73 Per Share In Cash At EV $11.3B; Deal Expected To Be Immediately Sales Accretive And EBITDA Pre Margin Post-Closing And EPS Pre Accretive By Year 3 Post-Closing
Merck KGaA, Darmstadt, Germany, a leading science and technology company, and Bio-Techne Corporation (NASDAQ:TECH), a Minneapolis-based global provider of life science tools, analytical technologies, and consumables,
▣Jun 24, 8:00 PMjournaltarget
Agent 6 — Options Momentum closed long 30 @ $12.08 (+$263.30)
De-risk: premium $12.08 ≥ 2.0× entry $3.30. Selling 30/100 contracts; trailing the remainder.
?Jun 24, 6:05 PMdecisionconsidered
Agent 20 — SIR Price/Volume — buy
[not executed — reserve_floor_or_cash] [accumulation] Over the 20-day path, TECH has traced a persistent up-and-right drift: the stock climbed from $48.09 (2026-05-27, 2.2M) to $58.86 (2026-06-24, 3.8M), a ~22% gain, with up-day volume consistently dominating down-day volume. Specifically, the four largest volume sessions — 2026-06-04 (4.2M, +4.58%), 2026-06-08 (4.4M, +1.27%), 2026-06-09 (3.6M, +3.34%), and today 2026-06-24 (3.8M, +4.62%) — were all UP days, while down-day volume was consistently muted (e.g., 2026-06-10 at 2.6M, 2026-06-16 at 1.5M, 2026-06-22 at 2.0M). Today's close at $58.86 on 3.8M (z-score +1.30 vs. the 20-day mean of 2.8M) marks a new path high on expanding volume, consistent with institutional accumulation rather than a single-bar anomaly. The macro tailwind — 10Y inflation expectations 2.0σ below trend (2.21 on 2026-06-23) — further supports long-duration Health Care names like TECH, as compressed real yields typically benefit growth-oriented healthcare multiples. Risks: A reversal back below the $56–$54 support band on elevated volume (>3.5M) would signal distribution overwhelming the accumulation read and invalidate the setup. Additionally, if 10Y inflation expectations snap back sharply toward trend, the macro tailwind for long-duration Health Care names would dissipate, removing a key supporting factor.
❖Jun 24, 4:16 PMnewsvia finnhub
Why Bio-Techne (TECH) Stock Is Trading Up Today
Shares of life sciences company Bio-Techne (NASDAQ:TECH) jumped 5.4% in the morning session after TD Cowen reiterated a Buy rating and a $65.00 price target on the stock.
?Jun 24, 10:25 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
TECH is up 6.81% intraday with no headline catalyst visible, suggesting this is flow-driven — likely a catalyst known to institutional participants (earnings revision, upgrade, or sector rotation) that preceded public headlines. A move of this magnitude represents genuine conviction from size players. However, several factors temper the continuation thesis: (1) With 320 minutes remaining (over 5 hours), there is ample time but also ample risk of mean reversion after a sharp gap/spike — large moves without news often see profit-taking as the session matures. (2) The macro context shows 10Y inflation breakevens (T10YIE) printing 2.0 sigma below trend, which is bullish for long-duration and growth-sensitive sectors like tech — this is a modest tailwind supporting the direction. (3) No reversals or fade patterns are noted; the move appears sustained from current data. (4) Absence of news does not disqualify, per framework. Overall, the balance of evidence supports a modest continuation bias — the macro backdrop is supportive, no fade signal is present, and the move size indicates real institutional flow — but the lack of a known catalyst and the risk of intraday exhaustion after a near-7% move cap confidence at a moderate level.
!Jun 24, 10:25 AMsignalseverity 0.07
Agent 7 — Day Trader — day_trade_skipped
TECH is up 6.81% intraday with no headline catalyst visible, suggesting this is flow-driven — likely a catalyst known to institutional participants (earnings revision, upgrade, or sector rotation) that preceded public headlines. A move of this magnitude represents genuine conviction from size players. However, several factors temper the continuation thesis: (1) With 320 minutes remaining (over 5 hours), there is ample time but also ample risk of mean reversion after a sharp gap/spike — large moves without news often see profit-taking as the session matures. (2) The macro context shows 10Y inflation breakevens (T10YIE) printing 2.0 sigma below trend, which is bullish for long-duration and growth-sensitive sectors like tech — this is a modest tailwind supporting the direction. (3) No reversals or fade patterns are noted; the move appears sustained from current data. (4) Absence of news does not disqualify, per framework. Overall, the balance of evidence supports a modest continuation bias — the macro backdrop is supportive, no fade signal is present, and the move size indicates real institutional flow — but the lack of a known catalyst and the risk of intraday exhaustion after a near-7% move cap confidence at a moderate level.
✓Jun 24, 9:51 AMdecisionacted
Agent 6 — Options Momentum — decide: buy
CALL on TECH — 5-day return 5.30% with close above 20-day MA ($53.54). IV 47.4%. Sized 1 contract(s) at $3.30 premium.
▢Jun 23, 8:00 PMjournal
Agent 6 — Options Momentum opened long 30 @ $3.30
?Jun 23, 9:36 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
TECH is up 1.65% today, a modest but real move suggesting genuine buying interest. There are no headlines to explain or catalyze the move, which is common and not disqualifying. The macro context is mildly supportive: T10YIE at 1.7σ below its 24-month trend implies compressed inflation expectations, which is favorable for long-duration sensitive sectors — and tech/growth equities are classically long-duration assets that benefit from lower real/nominal rates. With 369 minutes remaining (well over 6 hours, suggesting this is early-to-mid session), there is ample time for continuation. The move at 1.65% is below the 2-5% 'high conviction' threshold, so it doesn't carry strong momentum signal on its own. No reversal pattern is evident, and no fade cues are present. No volume data is available to confirm or deny institutional participation. On balance, the macro tailwind (low inflation expectations favoring long-duration growth) combined with time remaining and absence of fade signals tips this modestly toward continuation. Probability sits at the lower end of the ordinary momentum band — enough to take the trade given bounded risk parameters.
!Jun 23, 9:36 AMsignalseverity 0.02
Agent 7 — Day Trader — day_trade_skipped
TECH is up 1.65% today, a modest but real move suggesting genuine buying interest. There are no headlines to explain or catalyze the move, which is common and not disqualifying. The macro context is mildly supportive: T10YIE at 1.7σ below its 24-month trend implies compressed inflation expectations, which is favorable for long-duration sensitive sectors — and tech/growth equities are classically long-duration assets that benefit from lower real/nominal rates. With 369 minutes remaining (well over 6 hours, suggesting this is early-to-mid session), there is ample time for continuation. The move at 1.65% is below the 2-5% 'high conviction' threshold, so it doesn't carry strong momentum signal on its own. No reversal pattern is evident, and no fade cues are present. No volume data is available to confirm or deny institutional participation. On balance, the macro tailwind (low inflation expectations favoring long-duration growth) combined with time remaining and absence of fade signals tips this modestly toward continuation. Probability sits at the lower end of the ordinary momentum band — enough to take the trade given bounded risk parameters.
?Jun 22, 11:00 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
TECH is down 3.19% intraday with no attributable headline, suggesting this is flow/positioning-driven rather than news-driven. A move of this magnitude reflects real selling conviction. However, several factors temper the continuation case: (1) With 285 minutes remaining (nearly a full session still ahead), there is ample time but also ample time for mean reversion — this is not a late-day momentum lock-in scenario. (2) The macro context (5Y inflation breakevens 1.5σ below trend) is modestly deflationary, which is mixed for equities broadly and does not provide a clear sector-specific tailwind for continuation in TECH. (3) No news to anchor further selling means the move could be exhausting — large drops without catalysts often see afternoon recovery as dip buyers step in. (4) No volume data is provided to confirm whether selling pressure is sustained. Balancing the meaningful downside momentum (which itself is evidence of real flow) against the lack of a narrative anchor, ample time for reversal, and a mildly ambiguous macro backdrop, I assign a modest continuation probability just above the threshold. The bounded risk profile (-1.5% stop, +3% target) justifies taking the trade at this slim edge.
!Jun 22, 11:00 AMsignalseverity -0.03
Agent 7 — Day Trader — day_trade_skipped
TECH is down 3.19% intraday with no attributable headline, suggesting this is flow/positioning-driven rather than news-driven. A move of this magnitude reflects real selling conviction. However, several factors temper the continuation case: (1) With 285 minutes remaining (nearly a full session still ahead), there is ample time but also ample time for mean reversion — this is not a late-day momentum lock-in scenario. (2) The macro context (5Y inflation breakevens 1.5σ below trend) is modestly deflationary, which is mixed for equities broadly and does not provide a clear sector-specific tailwind for continuation in TECH. (3) No news to anchor further selling means the move could be exhausting — large drops without catalysts often see afternoon recovery as dip buyers step in. (4) No volume data is provided to confirm whether selling pressure is sustained. Balancing the meaningful downside momentum (which itself is evidence of real flow) against the lack of a narrative anchor, ample time for reversal, and a mildly ambiguous macro backdrop, I assign a modest continuation probability just above the threshold. The bounded risk profile (-1.5% stop, +3% target) justifies taking the trade at this slim edge.
▣Jun 21, 8:00 PMjournalstop
Agent 6 — Options Momentum closed long 100 @ $2.55 (-$29.23)
Stop: premium $2.55 ≤ trailing floor $2.62 (peak $3.49 × 0.75)
?Jun 18, 2:51 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
TECH is up 4.53% intraday with no attributable headline, suggesting institutional flow or sector rotation rather than a news-driven spike. A move of this magnitude reflects real conviction and is not easily dismissed. However, several factors temper continuation confidence: (1) Only 55 minutes remain until the forced 3:45 PM ET close, which significantly compresses the runway for further upside and increases the probability of profit-taking into the close. (2) The macro backdrop shows T10Y2Y at 3.5σ below its 24-month trend — a flat/inverted curve environment is not directly bearish for tech, but the anomalous rate signal introduces cross-asset uncertainty that could weigh on risk appetite late session. (3) No news catalyst means the move could be momentum-driven accumulation OR a large block trade that is now complete, leaving less follow-through fuel. (4) At 4.53% up, the stock is already near or past the system's +3% profit target threshold, meaning the asymmetric reward window may be partially consumed. Balancing the real but waning momentum signal against limited time and a mildly unfavorable macro backdrop, I assign a modest continuation probability just above the action threshold.
!Jun 18, 2:51 PMsignalseverity 0.05
Agent 7 — Day Trader — day_trade_skipped
TECH is up 4.53% intraday with no attributable headline, suggesting institutional flow or sector rotation rather than a news-driven spike. A move of this magnitude reflects real conviction and is not easily dismissed. However, several factors temper continuation confidence: (1) Only 55 minutes remain until the forced 3:45 PM ET close, which significantly compresses the runway for further upside and increases the probability of profit-taking into the close. (2) The macro backdrop shows T10Y2Y at 3.5σ below its 24-month trend — a flat/inverted curve environment is not directly bearish for tech, but the anomalous rate signal introduces cross-asset uncertainty that could weigh on risk appetite late session. (3) No news catalyst means the move could be momentum-driven accumulation OR a large block trade that is now complete, leaving less follow-through fuel. (4) At 4.53% up, the stock is already near or past the system's +3% profit target threshold, meaning the asymmetric reward window may be partially consumed. Balancing the real but waning momentum signal against limited time and a mildly unfavorable macro backdrop, I assign a modest continuation probability just above the action threshold.
✓Jun 18, 10:20 AMdecisionacted
Agent 6 — Options Momentum — decide: buy
CALL on TECH — 5-day return 5.12% with close above 20-day MA ($52.12). IV 39.8%. Sized 1 contract(s) at $2.85 premium.
▢Jun 17, 8:00 PMjournal
Agent 6 — Options Momentum opened long 100 @ $2.85
▣Jun 16, 8:00 PMjournalstop
Agent 6 — Options Momentum closed long 100 @ $1.85 (-$94.67)
Stop: premium $1.85 ≤ trailing floor $2.10 (peak $2.80 × 0.75)
❖Jun 15, 8:16 PMnewsvia finnhub
Bio-Techne (TECH) Stock Valuation After New Refeyn Bispecific Antibody Analysis Collaboration
Bio-Techne (TECH) has drawn fresh investor interest after teaming up with Refeyn on a four hour integrated workflow that links charge heterogeneity, molecular weight, and aggregation in bispecific antibodies and biosimilars at single molecule resolution. See our latest analysis for Bio-Techne. That Refeyn collaboration has landed at a time when momentum in Bio-Techne’s share price has picked up, with a 1 month share price return of 29.7% and a 90 day gain of 10%, even though the year to date...
?Jun 15, 9:56 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
TECH is up 4.22% intraday — a meaningful move reflecting real buying flow. The only headline is a cautious initiation from Piper Sandler noting patience on sector growth drivers, which is mildly negative sentiment but does not explain the move and does not constitute a catalyst that would sustain further buying. The macro backdrop (T10Y2Y at 2.2σ below trend, slight bear-flattening environment) is marginally unfavorable for growth/tech-adjacent names but TECH (Bio-Techne) is a life sciences tools company with some defensive characteristics, so macro drag is limited. With 349 minutes remaining there is ample time for continuation, which is a positive factor. However, the absence of a clear catalyst driving the move introduces uncertainty about whether the buying is exhausted or still has legs. No reversal signal is evident from the data provided. On balance, the move has momentum behind it and time remains, but the lack of a clear driver and the mildly cautious sector headline warrant only modest confidence. Assigning a slight lean toward continuation consistent with the system's borderline-resolve rule.
!Jun 15, 9:56 AMsignalseverity 0.04
Agent 7 — Day Trader — day_trade_skipped
TECH is up 4.22% intraday — a meaningful move reflecting real buying flow. The only headline is a cautious initiation from Piper Sandler noting patience on sector growth drivers, which is mildly negative sentiment but does not explain the move and does not constitute a catalyst that would sustain further buying. The macro backdrop (T10Y2Y at 2.2σ below trend, slight bear-flattening environment) is marginally unfavorable for growth/tech-adjacent names but TECH (Bio-Techne) is a life sciences tools company with some defensive characteristics, so macro drag is limited. With 349 minutes remaining there is ample time for continuation, which is a positive factor. However, the absence of a clear catalyst driving the move introduces uncertainty about whether the buying is exhausted or still has legs. No reversal signal is evident from the data provided. On balance, the move has momentum behind it and time remains, but the lack of a clear driver and the mildly cautious sector headline warrant only modest confidence. Assigning a slight lean toward continuation consistent with the system's borderline-resolve rule.
✓Jun 15, 9:47 AMdecisionacted
Agent 6 — Options Momentum — decide: buy
CALL on TECH — 5-day return 6.89% with close above 20-day MA ($50.56). IV 38.4%. Sized 1 contract(s) at $2.80 premium.
❖Jun 15, 4:47 AMnewsvia finnhub
'Activist Investor Ananym Urges Bio-Techne to Consider Selling' - Bloomberg News
https://www.bloomberg.com/news/articles/2026-06-15/activist-investor-ananym-urges-bio-techne-to-consider-selling
▢Jun 14, 8:00 PMjournal
Agent 6 — Options Momentum opened long 100 @ $2.80
▣Jun 10, 8:00 PMjournalstop
Agent 6 — Options Momentum closed long 100 @ $4.33 (-$86.30)
Stop: premium $4.33 ≤ trailing floor $4.39 (peak $5.86 × 0.75)
?Jun 9, 9:55 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
TECH is up 4.08% intraday with no attributable headline, suggesting this is flow-driven — likely institutional or systematic buying. A move of this magnitude represents real conviction and should not be dismissed. However, there are several moderating factors: (1) No news catalyst means the move could be vulnerable to profit-taking as the session progresses, especially after a 4%+ run. (2) The macro context shows T10Y2Y at 0.41, 2.0σ below its 24-month trend — a flattening/near-inverted yield curve typically pressures growth/tech names as it signals economic slowdown concerns. (3) 350 minutes remaining is substantial time, which cuts both ways — enough runway for continuation but also enough time for a fade. (4) Absence of headlines removes a potential re-acceleration catalyst. On balance, the raw momentum and size of the move slightly favor continuation into the close, but the yield curve backdrop is a meaningful headwind for a tech name specifically. Probability sits modestly above 0.5 — a weak continuation signal sufficient to take the trade given the bounded risk structure, but not a high-conviction setup.
!Jun 9, 9:55 AMsignalseverity 0.04
Agent 7 — Day Trader — day_trade_skipped
TECH is up 4.08% intraday with no attributable headline, suggesting this is flow-driven — likely institutional or systematic buying. A move of this magnitude represents real conviction and should not be dismissed. However, there are several moderating factors: (1) No news catalyst means the move could be vulnerable to profit-taking as the session progresses, especially after a 4%+ run. (2) The macro context shows T10Y2Y at 0.41, 2.0σ below its 24-month trend — a flattening/near-inverted yield curve typically pressures growth/tech names as it signals economic slowdown concerns. (3) 350 minutes remaining is substantial time, which cuts both ways — enough runway for continuation but also enough time for a fade. (4) Absence of headlines removes a potential re-acceleration catalyst. On balance, the raw momentum and size of the move slightly favor continuation into the close, but the yield curve backdrop is a meaningful headwind for a tech name specifically. Probability sits modestly above 0.5 — a weak continuation signal sufficient to take the trade given the bounded risk structure, but not a high-conviction setup.
?Jun 5, 2:55 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
TECH is down 2.91% intraday with no headline catalyst, suggesting this is flow/positioning driven rather than a news event that could reverse on clarification. The macro context shows T10Y2Y at 1.9σ below its 24-month trend — a flattening/near-inverted curve that favors defensives and pressures growth/tech names, providing a mild tailwind for continued selling pressure. With only 50 minutes remaining, there is limited runway for continuation, which caps the probability. No reversal pattern is evident (no mention of fade off lows or recovery attempt), and the move has been meaningful enough to suggest real conviction from sellers. However, the time constraint and absence of any supporting volume data or news anchor keep this in the modest continuation range rather than a high-conviction setup. Net assessment: slight lean toward continuation of the downside move into the close, but marginal.
!Jun 5, 2:55 PMsignalseverity -0.03
Agent 7 — Day Trader — day_trade_skipped
TECH is down 2.91% intraday with no headline catalyst, suggesting this is flow/positioning driven rather than a news event that could reverse on clarification. The macro context shows T10Y2Y at 1.9σ below its 24-month trend — a flattening/near-inverted curve that favors defensives and pressures growth/tech names, providing a mild tailwind for continued selling pressure. With only 50 minutes remaining, there is limited runway for continuation, which caps the probability. No reversal pattern is evident (no mention of fade off lows or recovery attempt), and the move has been meaningful enough to suggest real conviction from sellers. However, the time constraint and absence of any supporting volume data or news anchor keep this in the modest continuation range rather than a high-conviction setup. Net assessment: slight lean toward continuation of the downside move into the close, but marginal.
✓Jun 4, 11:15 AMdecisionacted
Agent 7 — Day Trader — decide: buy
TECH is up 3.72% intraday, which represents meaningful real-money flow and conviction. The headline (Bio-Techne/Refeyn partnership on bispecific antibody characterization) is modestly positive for the life sciences tools space but not a blockbuster catalyst — it reads more as a business update than a transformative event. With 270 minutes remaining (roughly 4.5 hours), there is ample time for the move to extend or at minimum hold into the close. The macro backdrop (T10Y2Y at 0.41, 2.1σ below trend) is modestly unfavorable for risk-on names if the market interprets flattening as a growth concern, but TECH/life sciences tools are not acutely rate-sensitive and do not map cleanly to the 'Banks negatively, Defensives' reactive sectors noted. No reversal signal or fade pattern is indicated. The move is in the meaningful 3-5% range suggesting institutional flow rather than retail noise. No strong reason to fade — assigning modest continuation probability above 0.5 reflecting genuine momentum without exceptional conviction.
✓Jun 4, 10:46 AMdecisionacted
Agent 8 — Dip Buyer (Peer-Aware) — pyramid
Pyramid add-on fired at +10.03% unrealized. Added 10 sh @ $52.78 ($527.80). Position now 31 sh @ weighted avg $49.52.
?Jun 4, 9:01 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
TECH is up 2.17% today with 405 minutes remaining (well over 6 hours, suggesting this is early-to-mid session), giving ample time for continuation. The headline references a product/partnership development (Bio-Techne/Refeyn bispecific antibody characterization) that is modestly positive for the life-sciences tools space — not a blockbuster catalyst, but directionally supportive. The macro context (T10Y2Y at 0.41, 2.1σ below 24-month trend) reflects a flattening/mild inversion environment that is somewhat unfavorable for cyclicals and banks but is broadly neutral-to-mildly supportive for growth/biotech names as it implies rate expectations are softening. No reversal signal is evident — the move is a clean up trend with no mention of fade from highs. Absent evidence of thin volume or a reversal pattern, the default lean per the framework is continuation. The 2.17% move represents real institutional flow. Probability stays modest rather than elevated because the news catalyst is incremental rather than transformational, and the macro backdrop is not strongly tailwind. Assigning 0.54 — a mild continuation lean, sufficient to trigger per the system rules, but not a high-conviction setup.
!Jun 4, 9:01 AMsignalseverity 0.02
Agent 7 — Day Trader — day_trade_skipped
TECH is up 2.17% today with 405 minutes remaining (well over 6 hours, suggesting this is early-to-mid session), giving ample time for continuation. The headline references a product/partnership development (Bio-Techne/Refeyn bispecific antibody characterization) that is modestly positive for the life-sciences tools space — not a blockbuster catalyst, but directionally supportive. The macro context (T10Y2Y at 0.41, 2.1σ below 24-month trend) reflects a flattening/mild inversion environment that is somewhat unfavorable for cyclicals and banks but is broadly neutral-to-mildly supportive for growth/biotech names as it implies rate expectations are softening. No reversal signal is evident — the move is a clean up trend with no mention of fade from highs. Absent evidence of thin volume or a reversal pattern, the default lean per the framework is continuation. The 2.17% move represents real institutional flow. Probability stays modest rather than elevated because the news catalyst is incremental rather than transformational, and the macro backdrop is not strongly tailwind. Assigning 0.54 — a mild continuation lean, sufficient to trigger per the system rules, but not a high-conviction setup.
?Jun 4, 7:02 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $43.66 cash available; close=$50.85.
!Jun 4, 7:02 AMsignal
Agent 5 — Dip Buyer (Evolving) — insufficient_capital
Wanted to buy but only $3.84 cash available; close=$50.85.
▢Jun 3, 8:00 PMjournal
Agent 7 — Day Trader opened long 28 @ $52.74
▣Jun 3, 8:00 PMjournalstop
Agent 7 — Day Trader closed long 28 @ $51.89 (-$23.94)
Long stop: close $51.88 ≤ stop $51.95
?Jun 3, 6:05 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $3.84 cash available; close=$50.85.
!Jun 3, 6:05 PMsignal
Agent 5 — Dip Buyer (Evolving) — insufficient_capital
Wanted to buy but only $1.04 cash available; close=$50.79.
?Jun 3, 10:37 AMdecisionconsidered
Agent 4 — Dip Buyer (Frozen) — decide: skip
There are no news headlines or SEC filings in the 30-day window to explain the 18.7% drop, suggesting it may be driven by macro rotation or sector-level selling pressure rather than company-specific deterioration. The T10Y3M spread is elevated at 0.76 (1.6σ above trend), indicating a steepening yield curve environment that tends to pressure growth/tech names and favor cyclicals and banks, which could explain continued headwinds for TECH. With no fundamental evidence to anchor a recovery thesis and an unfavorable macro backdrop for the sector, confidence in a rebound to the 30-day high within 90 days is limited.
!Jun 3, 10:37 AMsignalseverity 0.18
Agent 4 — Dip Buyer (Frozen) — dip_skipped
There are no news headlines or SEC filings in the 30-day window to explain the 18.7% drop, suggesting it may be driven by macro rotation or sector-level selling pressure rather than company-specific deterioration. The T10Y3M spread is elevated at 0.76 (1.6σ above trend), indicating a steepening yield curve environment that tends to pressure growth/tech names and favor cyclicals and banks, which could explain continued headwinds for TECH. With no fundamental evidence to anchor a recovery thesis and an unfavorable macro backdrop for the sector, confidence in a rebound to the 30-day high within 90 days is limited.
?Jun 3, 10:36 AMdecisionconsidered
Agent 4 — Dip Buyer (Frozen) — decide: skip
There are no news headlines or SEC filings in the 30-day window to explain the 18.7% drop, suggesting it may be driven by macro rotation or sector-level selling pressure rather than company-specific deterioration. The T10Y3M spread is elevated at 0.76 (1.6σ above trend), indicating a steepening yield curve environment that tends to pressure growth/tech names and favor cyclicals and banks, which could explain continued headwinds for TECH. With no fundamental evidence to anchor a recovery thesis and an unfavorable macro backdrop for the sector, confidence in a rebound to the 30-day high within 90 days is limited.
?Jun 3, 9:06 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
TECH is down 2.01% intraday with no attributable headline, suggesting institutional selling or sector rotation rather than a news-driven spike that might quickly reverse. The macro context shows T10Y2Y at 2.0σ below its 24-month trend, indicating a flattening/slightly inverted curve environment that tends to pressure growth/tech names as risk appetite softens and discount rates remain a concern. With 400 minutes remaining (well over 6 hours, which far exceeds the trading day — interpreting this as likely ~75-90 minutes to the 3:45 ET cutoff based on typical session timing), there is meaningful time for the move to extend. No reversal signals are explicitly present, and the absence of news does not disqualify momentum. However, the move is modest at ~2% and without confirming volume data or a clear catalyst, conviction is limited. Rating continuation probability at 0.52 — slight lean toward continuation given macro headwinds for tech and sustained selling pressure, but not a high-conviction setup.
!Jun 3, 9:06 AMsignalseverity -0.02
Agent 7 — Day Trader — day_trade_skipped
TECH is down 2.01% intraday with no attributable headline, suggesting institutional selling or sector rotation rather than a news-driven spike that might quickly reverse. The macro context shows T10Y2Y at 2.0σ below its 24-month trend, indicating a flattening/slightly inverted curve environment that tends to pressure growth/tech names as risk appetite softens and discount rates remain a concern. With 400 minutes remaining (well over 6 hours, which far exceeds the trading day — interpreting this as likely ~75-90 minutes to the 3:45 ET cutoff based on typical session timing), there is meaningful time for the move to extend. No reversal signals are explicitly present, and the absence of news does not disqualify momentum. However, the move is modest at ~2% and without confirming volume data or a clear catalyst, conviction is limited. Rating continuation probability at 0.52 — slight lean toward continuation given macro headwinds for tech and sustained selling pressure, but not a high-conviction setup.
✓Jun 3, 7:02 AMdecisionacted
Agent 5 — Dip Buyer (Evolving) — decide: buy
Wanted to buy but only $1.04 cash available; close=$50.79.
✓Jun 2, 6:04 PMdecisionacted
Agent 5 — Dip Buyer (Evolving) — decide: buy
Wanted to buy but only $1.04 cash available; close=$50.79.
?Jun 2, 3:30 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
With only 15 minutes remaining until the forced close, there is very little time for the move to extend meaningfully. The -1.81% decline is a moderate move but not extreme enough to signal a panic washout that typically runs further. The macro context (T10Y2Y at 2.0σ below trend, bear-flattening signal) is modestly negative for risk assets but TECH is not a bank or classic defensive sector — the macro signal is not a strong directional driver here. No headlines to confirm or deny a thesis. The critical factor is time: 15 minutes is insufficient runway for a continuation trade given the system's +3% profit target — even with tight stops, the expected value of initiating a short-side momentum trade in the final 15 minutes is negative when the move is sub-2% and there is no catalytic news or volume confirmation available. Late-session dynamics also introduce mean-reversion risk as institutional desks flatten positions into the close. Probability set below 0.5 primarily due to time constraint and absence of any continuation catalyst.
!Jun 2, 3:30 PMsignalseverity -0.02
Agent 7 — Day Trader — day_trade_skipped
With only 15 minutes remaining until the forced close, there is very little time for the move to extend meaningfully. The -1.81% decline is a moderate move but not extreme enough to signal a panic washout that typically runs further. The macro context (T10Y2Y at 2.0σ below trend, bear-flattening signal) is modestly negative for risk assets but TECH is not a bank or classic defensive sector — the macro signal is not a strong directional driver here. No headlines to confirm or deny a thesis. The critical factor is time: 15 minutes is insufficient runway for a continuation trade given the system's +3% profit target — even with tight stops, the expected value of initiating a short-side momentum trade in the final 15 minutes is negative when the move is sub-2% and there is no catalytic news or volume confirmation available. Late-session dynamics also introduce mean-reversion risk as institutional desks flatten positions into the close. Probability set below 0.5 primarily due to time constraint and absence of any continuation catalyst.
?Jun 2, 10:05 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
TECH is down 2.15% intraday with no headline catalyst, suggesting this is flow/macro driven rather than a news spike that could quickly reverse. The macro context is modestly negative for risk assets: T10Y2Y at 0.42 is 2.0σ below trend, indicating a flattening or slightly bear-flattening curve environment, which tends to pressure growth/tech names as discount rates concerns linger and risk appetite softens. With 340 minutes remaining there is ample time for continuation, so the time factor does not compress the probability. However, the absence of any news means we cannot confirm institutional conviction, and a -2.15% move without a catalyst carries some mean-reversion risk as intraday sellers may have exhausted near-term supply. Balancing the macro headwind and momentum signal against the lack of a news anchor and no volume data to confirm strength, this is a borderline continuation setup. Probability sits just above 0.5, favoring a modest continuation trade with tight stop discipline.
!Jun 2, 10:05 AMsignalseverity -0.02
Agent 7 — Day Trader — day_trade_skipped
TECH is down 2.15% intraday with no headline catalyst, suggesting this is flow/macro driven rather than a news spike that could quickly reverse. The macro context is modestly negative for risk assets: T10Y2Y at 0.42 is 2.0σ below trend, indicating a flattening or slightly bear-flattening curve environment, which tends to pressure growth/tech names as discount rates concerns linger and risk appetite softens. With 340 minutes remaining there is ample time for continuation, so the time factor does not compress the probability. However, the absence of any news means we cannot confirm institutional conviction, and a -2.15% move without a catalyst carries some mean-reversion risk as intraday sellers may have exhausted near-term supply. Balancing the macro headwind and momentum signal against the lack of a news anchor and no volume data to confirm strength, this is a borderline continuation setup. Probability sits just above 0.5, favoring a modest continuation trade with tight stop discipline.
?Jun 2, 7:01 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $1.04 cash available; close=$50.79.
!Jun 2, 7:01 AMsignal
Agent 5 — Dip Buyer (Evolving) — insufficient_capital
Wanted to buy but only $2.27 cash available; close=$50.81.
?Jun 1, 6:03 PMdecisionconsidered
Agent 4 — Dip Buyer (Frozen) — decide: skip
There are no news headlines or SEC filings in the 30-day window to explain the 18.7% drop, suggesting it may be driven by macro rotation or sector-level selling pressure rather than company-specific deterioration. The T10Y3M spread is elevated at 0.76 (1.6σ above trend), indicating a steepening yield curve environment that tends to pressure growth/tech names and favor cyclicals and banks, which could explain continued headwinds for TECH. With no fundamental evidence to anchor a recovery thesis and an unfavorable macro backdrop for the sector, confidence in a rebound to the 30-day high within 90 days is limited.
!Jun 1, 6:03 PMsignalseverity 0.19
Agent 4 — Dip Buyer (Frozen) — dip_skipped
There are no news headlines or SEC filings in the 30-day window to explain the 18.7% drop, suggesting it may be driven by macro rotation or sector-level selling pressure rather than company-specific deterioration. The T10Y3M spread is elevated at 0.76 (1.6σ above trend), indicating a steepening yield curve environment that tends to pressure growth/tech names and favor cyclicals and banks, which could explain continued headwinds for TECH. With no fundamental evidence to anchor a recovery thesis and an unfavorable macro backdrop for the sector, confidence in a rebound to the 30-day high within 90 days is limited.
?Jun 1, 6:03 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $2.27 cash available; close=$50.81.
!Jun 1, 6:03 PMsignal
Agent 5 — Dip Buyer (Evolving) — insufficient_capital
Net signal score: +3. TECH (Bio-Techne) is down 17.3% from its 30-day high — a drop magnitude >=15% without any identified fundamental cause (+1 mean-reversion candidate). No earnings are visible within the 90-day window (+1 clean runway). The Health Care sector is underperforming the market (30d rel-strength rank 3/11 but down 5.86pts vs SPY over 30 days), suggesting the dip is at least partly sector-wide rather than idiosyncratic (+1). No hard veto conditions are present: no imminent earnings, no SEC filings flagging deterioration, no fundamental red flags. Macro is modestly constructive — VIX at the 19th percentile (low fear, no elevated-VIX penalty), the 2s10s spread is positive (+0.46pp, no inversion headwind), and the 10Y at 4.45% is just below the 4.5% headwind threshold (neutral for a defensive/value health-care name). No insider activity or unusual options flow were present to score positively or negatively. Starting from the ~57.5% base-rate anchor for a 15%+ dip without fundamental impairment, the +3 net score supports a modest upward adjustment, tempered by thin confirming signals (no insider buys, no unusual call flow, negative sector flow proxy today).
✓Jun 1, 7:03 AMdecisionacted
Agent 5 — Dip Buyer (Evolving) — decide: buy
Net signal score: +3. TECH (Bio-Techne) is down 17.3% from its 30-day high — a drop magnitude >=15% without any identified fundamental cause (+1 mean-reversion candidate). No earnings are visible within the 90-day window (+1 clean runway). The Health Care sector is underperforming the market (30d rel-strength rank 3/11 but down 5.86pts vs SPY over 30 days), suggesting the dip is at least partly sector-wide rather than idiosyncratic (+1). No hard veto conditions are present: no imminent earnings, no SEC filings flagging deterioration, no fundamental red flags. Macro is modestly constructive — VIX at the 19th percentile (low fear, no elevated-VIX penalty), the 2s10s spread is positive (+0.46pp, no inversion headwind), and the 10Y at 4.45% is just below the 4.5% headwind threshold (neutral for a defensive/value health-care name). No insider activity or unusual options flow were present to score positively or negatively. Starting from the ~57.5% base-rate anchor for a 15%+ dip without fundamental impairment, the +3 net score supports a modest upward adjustment, tempered by thin confirming signals (no insider buys, no unusual call flow, negative sector flow proxy today).
✓May 29, 6:03 PMdecisionacted
Agent 6 — Options Momentum — decide: buy
CALL on TECH — 5-day return 9.10% with close above 20-day MA ($48.58). IV 82.2%. Sized 1 contract(s) at $5.19 premium.
?May 29, 7:02 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $3.04 cash available; close=$50.84.
!May 29, 7:02 AMsignal
Agent 5 — Dip Buyer (Evolving) — insufficient_capital
Net signal score: +2. Positive signals fired for (1) drop magnitude ≥15% from 30-day high without any identifiable fundamental cause (no SEC filings, no headlines, no guidance cuts), and (2) no earnings within 30 days, providing a clean 90-day runway. The sector (Health Care / XLV) shows modest positive 5-day relative strength vs SPY (+0.75pts) and today's sector flow proxy is strongly positive (+21.7M), suggesting the drop may be idiosyncratic noise rather than systemic deterioration. Macro context is benign: VIX at 46th percentile is neutral, the yield curve is positively sloped (+49bps 2s10s), and broad market tone today is constructive (SPY +0.55%, VXX -1.84%). No insider activity, options flow, or fundamental filings were available to add conviction in either direction. The base-rate anchor of ~55-60% for a ≥15% dip recovery in 90 days with no fundamental impairment, combined with the net +2 score and clean macro, supports a modest buy with probability calibrated to the low end of the +2 range given the near-total absence of confirmatory microstructure signals.
✓May 29, 7:01 AMdecisionacted
Agent 6 — Options Momentum — decide: buy
CALL on TECH — 5-day return 8.87% with close above 20-day MA ($48.76). IV 85.3%. Sized 2 contract(s) at $5.37 premium.
▢May 28, 8:00 PMjournal
Agent 6 — Options Momentum opened long 100 @ $5.19
?May 28, 6:01 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $12.25 cash available; close=$48.09.
!May 28, 6:01 PMsignal
Agent 5 — Dip Buyer (Evolving) — insufficient_capital
Wanted to buy but only $1.29 cash available; close=$48.09.
?May 28, 6:01 PMdecisionconsidered
Agent 4 — Dip Buyer (Frozen) — decide: skip
The 28.9% drop from the 30-day high is severe, but available news does not indicate fundamental deterioration — there are no guidance cuts, accounting issues, or sector collapse signals. Bio-Techne recently had an earnings call (Q1) and passed a qualitative screening filter, suggesting the business remains operationally intact. However, the macro context shows elevated 10-year inflation expectations (2.4σ above trend), which creates meaningful headwinds for long-duration, growth-oriented life sciences names like TECH, and the absence of recent SEC filings leaves uncertainty about the Q1 earnings details that may have triggered the sell-off.
!May 28, 6:01 PMsignalseverity 0.23
Agent 4 — Dip Buyer (Frozen) — dip_skipped
The 28.9% drop from the 30-day high is severe, but available news does not indicate fundamental deterioration — there are no guidance cuts, accounting issues, or sector collapse signals. Bio-Techne recently had an earnings call (Q1) and passed a qualitative screening filter, suggesting the business remains operationally intact. However, the macro context shows elevated 10-year inflation expectations (2.4σ above trend), which creates meaningful headwinds for long-duration, growth-oriented life sciences names like TECH, and the absence of recent SEC filings leaves uncertainty about the Q1 earnings details that may have triggered the sell-off.
?May 28, 11:11 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
TECH is up 4.02% intraday with no headline catalyst, suggesting this is flow/positioning-driven rather than news-driven. The move is meaningful in magnitude and represents real conviction from someone with size. However, several factors temper enthusiasm: (1) With 275 minutes remaining (~4.6 hours), there is ample time but also ample time for a fade or consolidation after a 4% move — late-session profit-taking is common after a gap/surge of this size. (2) The macro backdrop shows T10Y3M at 1.8σ above trend, indicating a steepening yield curve that is net neutral-to-mildly positive for growth/tech names (not a headwind, but not a tailwind either). (3) No news confirms a fundamental catalyst, which slightly increases fade risk relative to a news-driven move. (4) No reversal pattern is evident from the data provided, and absence of news is not disqualifying. On balance, the default lean is continuation given the system's asymmetric payoff structure (bounded downside via stops, fixed upside target), but the setup is ordinary momentum without strong confirming signals, placing this in the 0.5–0.65 range.
!May 28, 11:11 AMsignalseverity 0.04
Agent 7 — Day Trader — day_trade_skipped
TECH is up 4.02% intraday with no headline catalyst, suggesting this is flow/positioning-driven rather than news-driven. The move is meaningful in magnitude and represents real conviction from someone with size. However, several factors temper enthusiasm: (1) With 275 minutes remaining (~4.6 hours), there is ample time but also ample time for a fade or consolidation after a 4% move — late-session profit-taking is common after a gap/surge of this size. (2) The macro backdrop shows T10Y3M at 1.8σ above trend, indicating a steepening yield curve that is net neutral-to-mildly positive for growth/tech names (not a headwind, but not a tailwind either). (3) No news confirms a fundamental catalyst, which slightly increases fade risk relative to a news-driven move. (4) No reversal pattern is evident from the data provided, and absence of news is not disqualifying. On balance, the default lean is continuation given the system's asymmetric payoff structure (bounded downside via stops, fixed upside target), but the setup is ordinary momentum without strong confirming signals, placing this in the 0.5–0.65 range.
?May 28, 10:16 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
TECH is up 3.49% intraday, which represents meaningful real flow and conviction from size participants. No headlines are present, but absence of news does not disqualify — this move reflects genuine buying pressure. With 330 minutes remaining (essentially a full trading day still ahead, suggesting this is an early-session read), there is ample time for continuation. However, several factors temper enthusiasm: (1) The macro context shows T10Y3M at 1.8σ above its 24-month trend, signaling a steeper yield curve environment that can pressure growth/tech names as rate expectations shift — this is a mild headwind for TECH-sector continuation. (2) No catalyst is identifiable to sustain the move or attract additional buyers into the close. (3) The 3.49% move is already at the upper end of the 2-5% range, meaning a portion of near-term upside may already be captured. Balancing strong initial momentum and ample time remaining against macro headwinds and no identifiable catalyst, this is an ordinary momentum setup — probability sits just above the 0.5 threshold, warranting a long position with disciplined stop and target management.
!May 28, 10:16 AMsignalseverity 0.03
Agent 7 — Day Trader — day_trade_skipped
TECH is up 3.49% intraday, which represents meaningful real flow and conviction from size participants. No headlines are present, but absence of news does not disqualify — this move reflects genuine buying pressure. With 330 minutes remaining (essentially a full trading day still ahead, suggesting this is an early-session read), there is ample time for continuation. However, several factors temper enthusiasm: (1) The macro context shows T10Y3M at 1.8σ above its 24-month trend, signaling a steeper yield curve environment that can pressure growth/tech names as rate expectations shift — this is a mild headwind for TECH-sector continuation. (2) No catalyst is identifiable to sustain the move or attract additional buyers into the close. (3) The 3.49% move is already at the upper end of the 2-5% range, meaning a portion of near-term upside may already be captured. Balancing strong initial momentum and ample time remaining against macro headwinds and no identifiable catalyst, this is an ordinary momentum setup — probability sits just above the 0.5 threshold, warranting a long position with disciplined stop and target management.
?May 28, 7:01 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $1.29 cash available; close=$48.09.
!May 28, 7:01 AMsignal
Agent 5 — Dip Buyer (Evolving) — insufficient_capital
Wanted to buy but only $0.00 cash available; close=$47.97.
?May 27, 6:01 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $0.00 cash available; close=$47.97.
?May 27, 6:01 PMdecisionconsidered
Agent 4 — Dip Buyer (Frozen) — decide: skip
The 28.9% drop from the 30-day high is severe, but available news does not indicate fundamental deterioration — there are no guidance cuts, accounting issues, or sector collapse signals. Bio-Techne recently had an earnings call (Q1) and passed a qualitative screening filter, suggesting the business remains operationally intact. However, the macro context shows elevated 10-year inflation expectations (2.4σ above trend), which creates meaningful headwinds for long-duration, growth-oriented life sciences names like TECH, and the absence of recent SEC filings leaves uncertainty about the Q1 earnings details that may have triggered the sell-off.
!May 27, 6:01 PMsignalseverity 0.23
Agent 4 — Dip Buyer (Frozen) — dip_skipped
The 28.9% drop from the 30-day high is severe, but available news does not indicate fundamental deterioration — there are no guidance cuts, accounting issues, or sector collapse signals. Bio-Techne recently had an earnings call (Q1) and passed a qualitative screening filter, suggesting the business remains operationally intact. However, the macro context shows elevated 10-year inflation expectations (2.4σ above trend), which creates meaningful headwinds for long-duration, growth-oriented life sciences names like TECH, and the absence of recent SEC filings leaves uncertainty about the Q1 earnings details that may have triggered the sell-off.
!May 27, 6:01 PMsignal
Agent 5 — Dip Buyer (Evolving) — insufficient_capital
Wanted to buy but only $0.00 cash available; close=$47.97.
✓May 27, 6:01 PMdecisionacted
Agent 8 — Dip Buyer (Peer-Aware) — decide: buy
Wanted to buy but only $0.00 cash available; close=$48.21.
?May 27, 7:01 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $0.00 cash available; close=$47.97.
!May 27, 7:01 AMsignal
Agent 5 — Dip Buyer (Evolving) — insufficient_capital
Wanted to buy but only $22.31 cash available; close=$48.21.
✓May 27, 7:01 AMdecisionacted
Agent 8 — Dip Buyer (Peer-Aware) — decide: buy
Wanted to buy but only $0.00 cash available; close=$48.21.
▢May 26, 8:00 PMjournal
Agent 8 — Dip Buyer (Peer-Aware) opened long 15 @ $49.52
?May 26, 6:01 PMdecisionconsidered
Agent 4 — Dip Buyer (Frozen) — decide: skip
The 28.9% drop from the 30-day high is severe, but available news does not indicate fundamental deterioration — there are no guidance cuts, accounting issues, or sector collapse signals. Bio-Techne recently had an earnings call (Q1) and passed a qualitative screening filter, suggesting the business remains operationally intact. However, the macro context shows elevated 10-year inflation expectations (2.4σ above trend), which creates meaningful headwinds for long-duration, growth-oriented life sciences names like TECH, and the absence of recent SEC filings leaves uncertainty about the Q1 earnings details that may have triggered the sell-off.
?May 26, 6:01 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $22.31 cash available; close=$48.21.
!May 26, 6:01 PMsignalseverity 0.23
Agent 4 — Dip Buyer (Frozen) — dip_skipped
The 28.9% drop from the 30-day high is severe, but available news does not indicate fundamental deterioration — there are no guidance cuts, accounting issues, or sector collapse signals. Bio-Techne recently had an earnings call (Q1) and passed a qualitative screening filter, suggesting the business remains operationally intact. However, the macro context shows elevated 10-year inflation expectations (2.4σ above trend), which creates meaningful headwinds for long-duration, growth-oriented life sciences names like TECH, and the absence of recent SEC filings leaves uncertainty about the Q1 earnings details that may have triggered the sell-off.
!May 26, 6:01 PMsignal
Agent 5 — Dip Buyer (Evolving) — insufficient_capital
Wanted to buy but only $0.00 cash available; close=$48.21.
✓May 26, 6:01 PMdecisionacted
Agent 8 — Dip Buyer (Peer-Aware) — decide: buy
Wanted to buy but only $0.00 cash available; close=$48.21.
?May 26, 7:03 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $0.00 cash available; close=$48.21.
!May 26, 7:03 AMsignal
Agent 5 — Dip Buyer (Evolving) — insufficient_capital
Net signal score: +1. Positive signals: drop magnitude >=15% from 30-day high without an identifiable fundamental cause (+1), no earnings in visible window (+1), sector showing modest 5-day outperformance vs SPY (+2.43pts) suggesting the drop may be somewhat idiosyncratic but not catastrophically so. Negative signals: Health Care sector is a weak performer (rank 7 of 11, -7.99pts vs SPY on 30d basis) which partially offsets the drop-as-mean-reversion thesis; 10Y yield at 4.57% is above the ~4.5% threshold and represents a structural headwind for growth-sensitive names (-1); no insider buying, no options flow, and no SEC filings leave the thesis data-sparse. The net score of +1 is marginal with no strong anchor signal (no cluster buy, no unusual call flow), so conviction remains low. The 22.8% drawdown is significant and supports mean-reversion at the base rate, but the lack of any confirming signals keeps probability near the lower end of the marginal range.
?May 26, 7:02 AMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip_no_cash
Wanted to buy but only $0.00 cash available; close=$48.21.
?May 22, 6:01 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
STEP 1 — No hard veto fires outright: no imminent earnings visible, no 10-Q/8-K with guidance cuts or going-concern language, and while Health Care is a weak sector it is not in freefall (week-over-week sector data does not confirm >5% weekly drop with simultaneous credit stress). STEP 2 — Signal scoring: POSITIVE: (1) Drop magnitude >=15% from 30-day high without confirmed fundamental cause (+1, mean-reversion candidate — 30.7% decline is substantial); (2) Sector is underperforming market — XLV ranks 10 of 11 by 30-day relative strength, -13.87pts vs SPY over 30 days, suggesting the dip is at least partly sector-wide rather than purely idiosyncratic (+1); (3) No earnings within visible window (+1, clean runway). NEGATIVE: (1) No insider buying activity whatsoever in 30 days — with a 30.7% decline, the complete absence of insider buying is a meaningful warning signal that insiders are not viewing this as a bargain (-1); (2) No options flow data to confirm unusual call activity — cannot score the positive signal, and absence of confirming flow is a soft negative (0, neutral but removes a potential +1); (3) Sector flow proxy is deeply negative today at -13.8M, compounding the sector weakness on a broadly risk-off day (-1); (4) 10Y yield at 4.47% is approaching but not exceeding 4.5% threshold — marginal headwind for a health-care biotech name, scoring neutral (0); (5) T5YIE at 2.7%, 2.5σ above 24-month trend signals elevated inflation expectations, a headwind for growth-oriented biotech names (-1); (6) Broad market tone is negative today (SPY -1.20%, IWM -2.41%, QQQ -1.51%) adding near-term momentum headwind (soft -0.5, rounded to 0 as macro tone is already reflected in sector flow signal). NET SCORE: +3 positives, -3 negatives = 0. A net score of 0 is marginal and per framework requires the single strongest positive to be a cluster insider buy or unusual call flow to justify a buy — neither is present. The absence of insider buying into a 30.7% drawdown is particularly concerning as a signal that those with the most information are not stepping in. Without a confirming insider or options signal, a net-zero score on a 30% drop stock in the weakest sector cohort does not clear the bar. STEP 3 — No hard veto but net score of 0 without the required confirming insider/options catalyst → sound=false. STEP 4 — Anchoring at 55-60% base rate, adjusted down for: zero insider buying signal (-8%), deeply negative sector flow and sector rank 10/11 (-5%), elevated inflation expectations as headwind for growth health care (-4%), net neutral signal score with no positive catalyst to anchor the thesis (-5%). Final estimate: ~38%.
?May 22, 6:01 PMdecisionconsidered
Agent 4 — Dip Buyer (Frozen) — decide: skip
The 28.9% drop from the 30-day high is severe, but available news does not indicate fundamental deterioration — there are no guidance cuts, accounting issues, or sector collapse signals. Bio-Techne recently had an earnings call (Q1) and passed a qualitative screening filter, suggesting the business remains operationally intact. However, the macro context shows elevated 10-year inflation expectations (2.4σ above trend), which creates meaningful headwinds for long-duration, growth-oriented life sciences names like TECH, and the absence of recent SEC filings leaves uncertainty about the Q1 earnings details that may have triggered the sell-off.
?May 22, 6:01 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
Bio-Techne (TECH) has fallen 30.7% from its 30-day high with no confirmed fundamental impairment — no negative earnings surprise, no guidance cut, and no insider selling visible in the filings. The stock passed the "Caviar Cruise Screen" per recent news, suggesting some analyst-level quality recognition. However, the sector (Health Care / XLV) is the 2nd worst performer in relative strength over 30 days (-13.87pts vs SPY), indicating the drop is at least partly sector-driven, which could persist. The macro backdrop is mixed: VIX is at the 50th percentile (not alarming), but 5-year inflation expectations are running 2.5σ above trend (a structural headwind for growth-oriented biotech tools names), and today's broad market is under pressure across all benchmarks. With no insider cluster buys, no unusual options call flow, no visible earnings catalyst, and heavy sector-wide selling pressure, confirmation signals are absent despite the lack of a clear fundamental break.
?May 22, 3:30 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
TECH is up 1.55% today, which is a modest but real move. However, with only 15 minutes remaining until the forced 3:45 PM ET close, there is minimal time for the trend to extend meaningfully toward the +3% profit target. The macro context (T10Y3M at 2.2σ above trend) is not directly bearish for a generic tech name but does signal a steepening/risk environment that is sector-neutral to mildly unfavorable. No headlines provide a catalyst to sustain buying pressure. At this point in the session, end-of-day profit-taking and position flattening are common, creating a slight headwind. The move magnitude (1.55%) is below the 2-5% threshold that would itself constitute strong conviction evidence. With the time constraint being the dominant factor — 15 minutes is insufficient for a +3% target to be hit and creates meaningful risk of a fade into the close — this setup does not clear the continuation threshold.
?May 22, 7:01 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
STEP 1 — No hard veto fires outright: no imminent earnings visible, no 10-Q/8-K with guidance cuts or going-concern language, and while Health Care is a weak sector it is not in freefall (week-over-week sector data does not confirm >5% weekly drop with simultaneous credit stress). STEP 2 — Signal scoring: POSITIVE: (1) Drop magnitude >=15% from 30-day high without confirmed fundamental cause (+1, mean-reversion candidate — 30.7% decline is substantial); (2) Sector is underperforming market — XLV ranks 10 of 11 by 30-day relative strength, -13.87pts vs SPY over 30 days, suggesting the dip is at least partly sector-wide rather than purely idiosyncratic (+1); (3) No earnings within visible window (+1, clean runway). NEGATIVE: (1) No insider buying activity whatsoever in 30 days — with a 30.7% decline, the complete absence of insider buying is a meaningful warning signal that insiders are not viewing this as a bargain (-1); (2) No options flow data to confirm unusual call activity — cannot score the positive signal, and absence of confirming flow is a soft negative (0, neutral but removes a potential +1); (3) Sector flow proxy is deeply negative today at -13.8M, compounding the sector weakness on a broadly risk-off day (-1); (4) 10Y yield at 4.47% is approaching but not exceeding 4.5% threshold — marginal headwind for a health-care biotech name, scoring neutral (0); (5) T5YIE at 2.7%, 2.5σ above 24-month trend signals elevated inflation expectations, a headwind for growth-oriented biotech names (-1); (6) Broad market tone is negative today (SPY -1.20%, IWM -2.41%, QQQ -1.51%) adding near-term momentum headwind (soft -0.5, rounded to 0 as macro tone is already reflected in sector flow signal). NET SCORE: +3 positives, -3 negatives = 0. A net score of 0 is marginal and per framework requires the single strongest positive to be a cluster insider buy or unusual call flow to justify a buy — neither is present. The absence of insider buying into a 30.7% drawdown is particularly concerning as a signal that those with the most information are not stepping in. Without a confirming insider or options signal, a net-zero score on a 30% drop stock in the weakest sector cohort does not clear the bar. STEP 3 — No hard veto but net score of 0 without the required confirming insider/options catalyst → sound=false. STEP 4 — Anchoring at 55-60% base rate, adjusted down for: zero insider buying signal (-8%), deeply negative sector flow and sector rank 10/11 (-5%), elevated inflation expectations as headwind for growth health care (-4%), net neutral signal score with no positive catalyst to anchor the thesis (-5%). Final estimate: ~38%.
▣May 19, 8:00 PMjournalstop
Agent 6 — Options Momentum closed long 200 @ $3.95 (-$153.38)
Stop: premium $3.95 ≤ trailing floor $4.02 (peak $5.36 × 0.75)
▢May 13, 8:00 PMjournal
Agent 6 — Options Momentum opened long 200 @ $4.72

← Back to dashboard